Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

58 trials with published results (14%)

Research Maturity

220 completed trials (55% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.0%

28 terminated out of 401 trials

Success Rate

88.7%

+2.2% vs benchmark

Late-Stage Pipeline

15%

59 trials in Phase 3/4

Results Transparency

26%

58 of 220 completed with results

Key Signals

58 with results89% success28 terminated

Data Visualizations

Phase Distribution

254Total
Not Applicable (67)
Early P 1 (3)
P 1 (47)
P 2 (78)
P 3 (46)
P 4 (13)

Trial Status

Completed220
Unknown102
Terminated28
Active Not Recruiting18
Withdrawn15
Recruiting11

Trial Success Rate

88.7%

Benchmark: 86.5%

Based on 220 completed trials

Clinical Trials (401)

Showing 20 of 20 trials
NCT07086222Phase 4Active Not Recruiting

Efficacy and Safety of NVX-CoV2705

NCT05997290Phase 2CompletedPrimary

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

NCT06478420Phase 1Active Not RecruitingPrimary

COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

NCT04590222CompletedPrimary

Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19

NCT05384899Completed

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

NCT06631287Phase 3Recruiting

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT05168813Phase 2CompletedPrimary

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

NCT04910269Phase 3Recruiting

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT05463068Phase 3Completed

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT07300839Phase 3Active Not Recruiting

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT04368728Phase 2CompletedPrimary

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

NCT06181292Phase 2CompletedPrimary

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

NCT05141058Phase 1RecruitingPrimary

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT04376593Early Phase 1Completed

PET/CT Imaging in COVID-19 Patients

NCT04578509CompletedPrimary

Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva

NCT04585945Completed

COVID-19 on Placental Gene Expression and Pathology

NCT07430410Not ApplicableNot Yet RecruitingPrimary

Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test

NCT04868903Not ApplicableCompletedPrimary

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT05911906Phase 4CompletedPrimary

An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.

NCT04839146Phase 1Completed

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

Scroll to load more

Research Network

Activity Timeline